Eads & Heald Investment Counsel reduced its position in Edwards Lifesciences Corporation (NYSE:EW) by 4.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,122 shares of the medical research company’s stock after selling 300 shares during the period. Eads & Heald Investment Counsel’s holdings in Edwards Lifesciences Corporation were worth $724,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Sabal Trust CO increased its position in Edwards Lifesciences Corporation by 0.5% in the second quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock worth $347,000 after buying an additional 14 shares during the last quarter. Alexandria Capital LLC boosted its stake in Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after buying an additional 19 shares during the period. Quadrant Capital Group LLC boosted its stake in Edwards Lifesciences Corporation by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock worth $109,000 after buying an additional 41 shares during the period. Rehmann Capital Advisory Group boosted its stake in Edwards Lifesciences Corporation by 1.6% in the first quarter. Rehmann Capital Advisory Group now owns 3,393 shares of the medical research company’s stock worth $319,000 after buying an additional 55 shares during the period. Finally, M Holdings Securities Inc. boosted its stake in Edwards Lifesciences Corporation by 1.5% in the first quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company’s stock worth $389,000 after buying an additional 62 shares during the period. Institutional investors own 83.80% of the company’s stock.

Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at 116.19 on Friday. The firm has a market capitalization of $24.53 billion, a PE ratio of 35.24 and a beta of 0.63. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75. The company’s 50 day moving average is $117.23 and its 200 day moving average is $104.41.

Edwards Lifesciences Corporation (NYSE:EW) last posted its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business had revenue of $842 million during the quarter, compared to analysts’ expectations of $839.16 million. During the same period in the prior year, the business earned $0.76 EPS. Edwards Lifesciences Corporation’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, analysts forecast that Edwards Lifesciences Corporation will post $3.64 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Eads & Heald Investment Counsel Sells 300 Shares of Edwards Lifesciences Corporation (EW)” was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/05/eads-heald-investment-counsel-sells-300-shares-of-edwards-lifesciences-corporation-ew.html.

A number of research firms recently weighed in on EW. BidaskClub raised shares of Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 22nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences Corporation in a report on Wednesday, June 28th. Zacks Investment Research cut shares of Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a report on Thursday, June 8th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $115.00 price objective on shares of Edwards Lifesciences Corporation in a report on Friday, June 30th. Finally, SunTrust Banks, Inc. increased their price objective on shares of Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a report on Monday, July 17th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. Edwards Lifesciences Corporation currently has an average rating of “Buy” and an average target price of $121.13.

In other Edwards Lifesciences Corporation news, VP Donald E. Bobo, Jr. sold 5,300 shares of the company’s stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $114.68, for a total transaction of $607,804.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Catherine M. Szyman sold 4,681 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $115.78, for a total value of $541,966.18. The disclosure for this sale can be found here. Over the last three months, insiders have sold 144,612 shares of company stock valued at $16,567,653. 2.13% of the stock is owned by company insiders.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.